Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Migraine

  Free Subscription


Articles published in Headache

Retrieve available abstracts of 239 articles:
HTML format



Single Articles


    November 2022
  1. KALTSEIS K, Hamann T, Gaul C, Broessner G, et al
    Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review.
    Headache. 2022 Nov 27. doi: 10.1111/head.14415.
    PubMed     Abstract available


  2. VIVES-MESTRES M, Casanova A, Puig X, Ginebra J, et al
    Alcohol as a trigger of migraine attacks in people with migraine. Results from a large prospective cohort study in English-speaking countries.
    Headache. 2022 Nov 27. doi: 10.1111/head.14428.
    PubMed     Abstract available


  3. SOUZA MNP, Cohen JM, Piha T, Ribalov R, et al
    Burden of migraine in Brazil: A cross-sectional real-world study.
    Headache. 2022 Nov 25. doi: 10.1111/head.14413.
    PubMed     Abstract available


  4. THAXTER LY, Smitherman TA
    The effect of the COVID-19 pandemic on headache-related disability among young adults with migraine.
    Headache. 2022 Nov 23. doi: 10.1111/head.14411.
    PubMed     Abstract available


  5. GUI T, Li H, Zhu F, Wang Q, et al
    Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials.
    Headache. 2022 Nov 14. doi: 10.1111/head.14423.
    PubMed     Abstract available


  6. HENNINGSEN P, Hausteiner-Wiehle C, Hauser W
    Migraine in the context of chronic primary pain, chronic overlapping pain disorders, and functional somatic disorders: A narrative review.
    Headache. 2022 Nov 14. doi: 10.1111/head.14419.
    PubMed     Abstract available


  7. GARCIA-AZORIN D
    The complex relationship between alcohol and migraine.
    Headache. 2022 Nov 14. doi: 10.1111/head.14426.
    PubMed    


  8. SENG EK, Shapiro RE, Buse DC, Robbins MS, et al
    The unique role of stigma in migraine-related disability and quality of life.
    Headache. 2022 Nov 2. doi: 10.1111/head.14401.
    PubMed     Abstract available


    October 2022
  9. CROOP R, Madonia J, Stock DA, Thiry A, et al
    Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
    Headache. 2022 Oct 14. doi: 10.1111/head.14389.
    PubMed     Abstract available


  10. GARELJA ML, Hay DL
    A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond.
    Headache. 2022 Oct 13. doi: 10.1111/head.14388.
    PubMed     Abstract available


  11. FOFI L, Altamura C, Fiorentini G, Brunelli N, et al
    Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment.
    Headache. 2022 Oct 7. doi: 10.1111/head.14400.
    PubMed     Abstract available


  12. HARPE J, Bernstein C, Harriott A
    Migraine and infertility, merging concepts in women's reproductive health: A narrative review.
    Headache. 2022 Oct 6. doi: 10.1111/head.14402.
    PubMed     Abstract available


  13. YONKER ME, McVige J, Zeitlin L, Visser H, et al
    A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.
    Headache. 2022;62:1207-1217.
    PubMed     Abstract available


  14. STERN JI, Chiang CC, Kissoon NR, Robertson CE, et al
    Narrative review of peripheral nerve blocks for the management of headache.
    Headache. 2022;62:1077-1092.
    PubMed     Abstract available


  15. FISCHER-SCHULTE L, May A
    The 15-day threshold in the definition of chronic migraine is reasonable and sufficient-Five reasons for not changing the ICHD-3 definition.
    Headache. 2022;62:1231-1233.
    PubMed    


  16. BELTRAMONE M, Redon S, Fernandes S, Ducros A, et al
    The teaching of headache medicine in France: A questionnaire-based study.
    Headache. 2022;62:1177-1186.
    PubMed     Abstract available


  17. ORR SL, Shapiro RE
    The elephant in the room: How the underfunding of headache research stunts the field.
    Headache. 2022;62:1234-1238.
    PubMed    


    September 2022
  18. BURCH R
    A non-oral gepant for acute treatment of migraine.
    Headache. 2022 Sep 16. doi: 10.1111/head.14397.
    PubMed    


  19. KUDROW D, Nguyen L, Semler J, Stroud C, et al
    A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist.
    Headache. 2022 Sep 16. doi: 10.1111/head.14390.
    PubMed     Abstract available


  20. LI D, Guo Y, Xia M, Zhang J, et al
    Dietary intake of thiamine and riboflavin in relation to severe headache or migraine: A cross-sectional survey.
    Headache. 2022 Sep 1. doi: 10.1111/head.14384.
    PubMed     Abstract available


  21. HUBIG LT, Smith T, Chua GN, Lloyd AJ, et al
    A stated preference survey to explore patient preferences for novel preventive migraine treatments.
    Headache. 2022 Sep 1. doi: 10.1111/head.14386.
    PubMed     Abstract available


    August 2022
  22. LOPEZ-BRAVO A, Oliveros-Cid A, Minguez-Olaondo A, Cuadrado ML, et al
    Nummular headache responsive to anti-calcitonin gene-related peptide monoclonal antibodies in a patient with migraine.
    Headache. 2022 Aug 26. doi: 10.1111/head.14372.
    PubMed     Abstract available


  23. OLIVEIRA AB, Peres MFP, Mercante JPP, Molina MDCB, et al
    Physical activity pattern and migraine according to aura symptoms in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) cohort: A cross-sectional study.
    Headache. 2022 Aug 26. doi: 10.1111/head.14380.
    PubMed     Abstract available


  24. MONTERREY P, Gonzalez M, Ramirez D, Gracia F, et al
    Characteristics of migraine in patients with headache disorders: A clinic-based study from Central American and Caribbean countries.
    Headache. 2022 Aug 26. doi: 10.1111/head.14375.
    PubMed     Abstract available


    July 2022
  25. NAGARAJ K, Wei DY, Puledda F, Weng HY, et al
    Comparison and predictors of chronic migraine vs. new daily persistent headache presenting with a chronic migraine phenotype.
    Headache. 2022 Jul 21. doi: 10.1111/head.14362.
    PubMed     Abstract available


  26. CHIANG CC, Schwedt TJ, Dodick DW
    Exploring the association between migraine and atrial fibrillation utilizing a novel artificial intelligence-ECG algorithm.
    Headache. 2022 Jul 21. doi: 10.1111/head.14366.
    PubMed    


  27. MUELLER BR, Robinson-Papp J
    Postural orthostatic tachycardia syndrome and migraine: A narrative review.
    Headache. 2022 Jul 19. doi: 10.1111/head.14365.
    PubMed     Abstract available


  28. LEE W, Cho SJ, Hwang H, Lee M, et al
    Crystal-clear days and unclear days in migraine: A population-based study.
    Headache. 2022 Jul 14. doi: 10.1111/head.14359.
    PubMed     Abstract available


  29. BEMANALIZADEH M, Baghaei Oskouei H, Hadizadeh A, Dakkali MS, et al
    Paroxysmal hemicrania in children and adolescents: A systematic review.
    Headache. 2022 Jul 14. doi: 10.1111/head.14354.
    PubMed     Abstract available


  30. MARTAMI F, Jayedi A, Shab-Bidar S
    Primary headache disorders and body mass index categories: A systematic review and dose-response meta-analysis.
    Headache. 2022;62:801-810.
    PubMed     Abstract available


  31. MOSKATEL LS, Smirnoff L
    Protracted headache after COVID-19: A case series of 31 patients from a tertiary headache center.
    Headache. 2022;62:903-907.
    PubMed     Abstract available


  32. RADZIWON J, Waszak P
    Seasonal changes of internet searching suggest circannual rhythmicity of primary headache disorders.
    Headache. 2022;62:811-817.
    PubMed     Abstract available


    June 2022
  33. TEPPER SJ, Grosberg B, Daniel O, Kuruvilla DE, et al
    Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized controlled trial.
    Headache. 2022 Jun 24. doi: 10.1111/head.14350.
    PubMed     Abstract available


  34. BERTELS Z, Mangutov E, Conway C, Siegersma K, et al
    Migraine and peripheral pain models show differential alterations in neuronal complexity.
    Headache. 2022 Jun 8. doi: 10.1111/head.14352.
    PubMed     Abstract available


  35. CHIANG CC, Chhabra N, Chao CJ, Wang H, et al
    Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men.
    Headache. 2022 Jun 8. doi: 10.1111/head.14339.
    PubMed     Abstract available


  36. PERO A, Pace A, Dhamoon MS
    Triptan medication use among patients with migraine with contraindications in the US.
    Headache. 2022 Jun 7. doi: 10.1111/head.14327.
    PubMed     Abstract available


  37. CASANOVA A, Vives-Mestres M, Donoghue S, Mian A, et al
    An observational study of self-reported migraine triggers and prospective evaluation of the relationships with occurrence of attacks enabled by a smartphone application (App).
    Headache. 2022 Jun 7. doi: 10.1111/head.14328.
    PubMed     Abstract available


  38. RICHER LP, Ali S, Johnson DW, Rosychuk RJ, et al
    A randomized trial of ketorolac and metoclopramide for migraine in the emergency department.
    Headache. 2022 Jun 7. doi: 10.1111/head.14307.
    PubMed     Abstract available


  39. BUOITE STELLA A, Filingeri D, Garascia G, D'Acunto L, et al
    Skin wetness sensitivity across body sites commonly affected by pain in people with migraine.
    Headache. 2022 Jun 7. doi: 10.1111/head.14323.
    PubMed     Abstract available


  40. GELFAND AA, Halker Singh RB, Robbins MS
    Worsening migraine: Another casualty of natural disasters.
    Headache. 2022 Jun 7. doi: 10.1111/head.14325.
    PubMed    


  41. COWAN RP, Rapoport AM, Blythe J, Rothrock J, et al
    Diagnostic accuracy of an artificial intelligence online engine in migraine: A multi-center study.
    Headache. 2022 Jun 3. doi: 10.1111/head.14324.
    PubMed     Abstract available


  42. SAMPAIO ROCHA-FILHO PA
    Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management.
    Headache. 2022;62:650-656.
    PubMed     Abstract available


    May 2022
  43. EZZATI A, Fanning KM, Buse DC, Pavlovic JM, et al
    Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study.
    Headache. 2022 May 11. doi: 10.1111/head.14312.
    PubMed     Abstract available


  44. LEE DA, Lee HJ, Park KM
    Normal glymphatic system function in patients with migraine: A pilot study.
    Headache. 2022 May 11. doi: 10.1111/head.14320.
    PubMed     Abstract available


  45. SCHWEDT TJ, Robert T, Dodick DW
    Treatment of chronic migraine with medication overuse: A perspective.
    Headache. 2022 May 6. doi: 10.1111/head.14314.
    PubMed    


  46. HSU TW, Chen MH, Chu CS, Tsai SJ, et al
    Attention deficit hyperactivity disorder and risk of migraine: A nationwide longitudinal study.
    Headache. 2022 May 6. doi: 10.1111/head.14306.
    PubMed     Abstract available


  47. KHAYATA MJ, Farley S, Davis JK, Hornik CP, et al
    Beyond pain control: Outcome and treatment preferences in pediatric migraine.
    Headache. 2022 May 6. doi: 10.1111/head.14315.
    PubMed     Abstract available


  48. SCHIM JD, Anderson C, Brunner E, Hirman J, et al
    Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
    Headache. 2022 May 6. doi: 10.1111/head.14302.
    PubMed     Abstract available


  49. CARVALHO GF, Luedtke K, Pinheiro CF, Moraes R, et al
    Migraine and balance impairment: Influence of subdiagnosis, otoneurological function, falls, and psychosocial factors.
    Headache. 2022;62:548-557.
    PubMed     Abstract available


  50. ASHINA M, Tepper SJ, Brandes JL, Reuter U, et al
    Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
    Headache. 2022;62:624-633.
    PubMed     Abstract available


  51. LEIBOVIT-REIBEN Z, Ishii R, Dodick DW, Dumkrieger G, et al
    The impact of pre-morbid headaches on headache features and long-term health outcomes following traumatic brain injury: Insights from the American Registry for Migraine Research.
    Headache. 2022;62:566-576.
    PubMed     Abstract available


  52. ZEBENHOLZER K, Gall W, Gleiss A, Pavelic AR, et al
    Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
    Headache. 2022;62:604-612.
    PubMed     Abstract available


  53. YOUSEF YENGEJ D, Nwaobi SE, Ferando I, Kechechyan G, et al
    Different characteristics of cortical spreading depression in the sleep and wake states.
    Headache. 2022;62:577-587.
    PubMed     Abstract available


    April 2022
  54. NAHMAN-AVERBUCH H, Schneider VJ 2nd, Lee GR, Peugh JL, et al
    New insight into the neural mechanisms of migraine in adolescents: Relationships with sleep.
    Headache. 2022 Apr 25. doi: 10.1111/head.14299.
    PubMed     Abstract available


  55. TU YH, Wang YF, Yuan H, Chen SP, et al
    Most bothersome symptoms in patients with migraine: A hospital-based study in Taiwan.
    Headache. 2022 Apr 25. doi: 10.1111/head.14308.
    PubMed     Abstract available


  56. VIG SJ, Garza J, Tao Y
    The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review.
    Headache. 2022 Apr 25. doi: 10.1111/head.14305.
    PubMed     Abstract available


  57. OKAZAKI Y, Yoshida S, Kashima S, Koike S, et al
    Impact of the 2018 Japan Floods on prescriptions for migraine: A longitudinal analysis using the National Database of Health Insurance Claims.
    Headache. 2022 Apr 25. doi: 10.1111/head.14301.
    PubMed     Abstract available


  58. LIPTON RB, Goadsby PJ, Dodick DW, McGinley JS, et al
    Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.
    Headache. 2022 Apr 25. doi: 10.1111/head.14295.
    PubMed     Abstract available


  59. BECKER WJ, Spacey S, Leroux E, Giammarco R, et al
    A real-world, observational study of erenumab for migraine prevention in Canadian patients.
    Headache. 2022 Apr 10. doi: 10.1111/head.14291.
    PubMed     Abstract available


  60. FERRARI MD, Zuurbier KWM, Barash S, Ning X, et al
    Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.
    Headache. 2022 Apr 6. doi: 10.1111/head.14294.
    PubMed    


  61. SILVESTRO M, Tessitore A, Orologio I, Battista G, et al
    Cluster headache pathophysiology: What we have learned from advanced neuroimaging.
    Headache. 2022;62:436-452.
    PubMed     Abstract available


    March 2022
  62. HARRIS L, L'Italien G, Kumar A, Seelam P, et al
    Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States.
    Headache. 2022 Mar 28. doi: 10.1111/head.14289.
    PubMed     Abstract available


  63. SENG EK, Lipton RB
    Do behavioral treatments work for migraine prevention?
    Headache. 2022 Mar 16. doi: 10.1111/head.14290.
    PubMed    


  64. BUSE DC, Gerstein MT, Houts CR, McGinley JS, et al
    Impact of the COVID-19 pandemic on people living with migraine: Results of the MiCOAS qualitative study.
    Headache. 2022 Mar 16. doi: 10.1111/head.14274.
    PubMed     Abstract available


  65. CARVALHO GF, Becnel AR, Miske C, Szikszay TM, et al
    Postural control impairment in patients with headaches-A systematic review and meta-analysis.
    Headache. 2022;62:241-270.
    PubMed     Abstract available


    February 2022
  66. AILANI J, Winner P, Hartry A, Brevig T, et al
    Patient preference for early onset of efficacy of preventive migraine treatments.
    Headache. 2022 Feb 20. doi: 10.1111/head.14255.
    PubMed     Abstract available


  67. GRECO R, Demartini C, Zanaboni AM, Francavilla M, et al
    The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain.
    Headache. 2022 Feb 18. doi: 10.1111/head.14267.
    PubMed     Abstract available


  68. KLAN T, Brascher AK, Klein S, Diezemann-Prossdorf A, et al
    Assessing attack-related fear in headache disorders-Structure and psychometric properties of the Fear of Attacks in Migraine Inventory.
    Headache. 2022 Feb 18. doi: 10.1111/head.14272.
    PubMed     Abstract available


  69. TIETJEN GE
    The relationship of childhood adversity and migraine and the value of prospective studies.
    Headache. 2022 Feb 9. doi: 10.1111/head.14268.
    PubMed    


  70. TEPPER SJ, Sheikh HU, Dougherty CO, Nahas SJ, et al
    Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations.
    Headache. 2022 Feb 9. doi: 10.1111/head.14266.
    PubMed     Abstract available


  71. KAWATA AK, Ladd MK, Lipton RB, Buse DC, et al
    Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials.
    Headache. 2022 Feb 8. doi: 10.1111/head.14258.
    PubMed     Abstract available


  72. DUDENEY J, Sharpe L, McDonald S, Menzies RE, et al
    Are psychological interventions efficacious for adults with migraine? A systematic review and meta-analysis.
    Headache. 2022 Feb 5. doi: 10.1111/head.14260.
    PubMed     Abstract available


  73. DI ANTONIO S, Castaldo M, Ponzano M, Bovis F, et al
    Trigeminal and cervical sensitization during the four phases of the migraine cycle in patients with episodic migraine.
    Headache. 2022 Feb 5. doi: 10.1111/head.14261.
    PubMed     Abstract available


  74. GOLLION C, Guidolin B, Lerebours F, Rousseau V, et al
    Migraine and large artery atherosclerosis in young adults with ischemic stroke.
    Headache. 2022 Feb 5. doi: 10.1111/head.14265.
    PubMed     Abstract available


  75. HAMMOND NG, Colman I, Orr SL
    Adverse childhood experiences and onset of migraine in Canadian adolescents: A cohort study.
    Headache. 2022 Feb 5. doi: 10.1111/head.14256.
    PubMed     Abstract available


  76. GIL YE, Lee MJ, Cho S, Chung CS, et al
    Effect of caffeine and caffeine cessation on cerebrovascular reactivity in patients with migraine.
    Headache. 2022 Feb 3. doi: 10.1111/head.14263.
    PubMed     Abstract available


  77. SHAO Q, Rascati KL, Barner JC, Lawson KA, et al
    Healthcare utilization and costs among patients with chronic migraine, episodic migraine, and tension-type headache enrolled in commercial insurance plans.
    Headache. 2022;62:141-158.
    PubMed     Abstract available


  78. AILANI J, Kuruppu DK, Rettiganti M, Oakes T, et al
    Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.
    Headache. 2022;62:198-207.
    PubMed     Abstract available


    January 2022
  79. LIPTON RB, Nicholson RA, Reed ML, Araujo AB, et al
    Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study.
    Headache. 2022 Jan 25. doi: 10.1111/head.14259.
    PubMed     Abstract available


  80. ARTEMENKO AR, Filatova E, Vorobyeva YD, Do TP, et al
    Migraine and light: A narrative review.
    Headache. 2022;62:4-10.
    PubMed     Abstract available


  81. ELSER H, Skajaa N, Ehrenstein V, Fuglsang CH, et al
    Cancer risk in patients with migraine: A population-based cohort study in Denmark.
    Headache. 2022;62:57-64.
    PubMed     Abstract available


    December 2021
  82. MASON BN, Kallianpur R, Price TJ, Akopian AN, et al
    Prolactin signaling modulates stress-induced behavioral responses in a preclinical mouse model of migraine.
    Headache. 2021 Dec 29. doi: 10.1111/head.14248.
    PubMed     Abstract available


  83. LIPTON RB, Gandhi P, Stokes J, Cala ML, et al
    Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.
    Headache. 2021 Dec 28. doi: 10.1111/head.14229.
    PubMed     Abstract available


  84. AILANI J, Blumenfeld AM
    Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.
    Headache. 2021 Dec 7. doi: 10.1111/head.14244.
    PubMed    


  85. BURCH RC, Ailani J, Robbins MS
    The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
    Headache. 2021 Dec 7. doi: 10.1111/head.14245.
    PubMed    


  86. OLIVEIRA ADP, Silva-Neto RP
    Circadian rhythmicity on red ear syndrome in a patient with migraine: A case report.
    Headache. 2021 Dec 7. doi: 10.1111/head.14242.
    PubMed     Abstract available


  87. GONZALEZ-MARTINEZ A, Trillo Senin S, Benavides Bernaldo de Queiros C, Casado Fernandez L, et al
    Clinical characteristics and perfusion-computed tomography alterations in a series of patients with migraine with aura attended as stroke code.
    Headache. 2021 Dec 3. doi: 10.1111/head.14243.
    PubMed     Abstract available


    November 2021
  88. CHARLES JA, Turner IM
    AHS 2021 consensus on integrating new migraine therapies into clinical practice: Isn't our goal choice of best therapy regardless of cost?
    Headache. 2021 Nov 28. doi: 10.1111/head.14232.
    PubMed    


  89. MCALLISTER PJ, Turner I, Reuter U, Wang A, et al
    Timing and durability of response to erenumab in patients with episodic migraine.
    Headache. 2021 Nov 28. doi: 10.1111/head.14233.
    PubMed     Abstract available


  90. LEE JH, Shewale AR, Barthold D, Devine B, et al
    Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
    Headache. 2021 Nov 28. doi: 10.1111/head.14238.
    PubMed     Abstract available


  91. OZKAN E, Gursoy-Ozdemir Y
    Occipital bending in migraine with visual aura.
    Headache. 2021 Nov 28. doi: 10.1111/head.14240.
    PubMed     Abstract available


  92. GLADSTONE J, Chhibber S, Minhas J, Neish CS, et al
    Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study.
    Headache. 2021 Nov 22. doi: 10.1111/head.14218.
    PubMed     Abstract available


  93. KAZI F, Manyapu M, Fakherddine M, Mekuria K, et al
    Second-line interventions for migraine in the emergency department: A narrative review.
    Headache. 2021 Nov 22. doi: 10.1111/head.14239.
    PubMed     Abstract available


  94. CHARLES A, Nwaobi SE, Goadsby P
    Inflammation in migraine...or not...: A critical evaluation of the evidence.
    Headache. 2021 Nov 22. doi: 10.1111/head.14224.
    PubMed    


  95. VYAS MV, Saposnik G, Lay C
    Migraine and sun avoidance behaviors in Canadian adults.
    Headache. 2021 Nov 2. doi: 10.1111/head.14227.
    PubMed    


  96. RAGAB AH, Kishk NA, Hassan A, Yacoub O, et al
    Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study.
    Headache. 2021 Nov 2. doi: 10.1111/head.14231.
    PubMed     Abstract available


  97. HINDIYEH N
    Can we anticipate how Ramadan fasting will affect migraine?
    Headache. 2021;61:1463-1464.
    PubMed    


  98. KELLY AM, Kuan WS, Chu KH, Kinnear FB, et al
    Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)-A multinational observational study.
    Headache. 2021;61:1539-1552.
    PubMed     Abstract available


    October 2021
  99. YUAN H, Curran JG, Keith SW, Hopkins MM, et al
    Intravenous ibuprofen for acute treatment of migraine: A double-blind, randomized, placebo-controlled pilot study.
    Headache. 2021 Oct 3. doi: 10.1111/head.14214.
    PubMed     Abstract available


  100. GALLARDO VJ, Alpuente A, Cerda-Company X, Torres-Ferrus M, et al
    The impact of a digital platform on migraine patient-centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish.
    Headache. 2021 Oct 3. doi: 10.1111/head.14225.
    PubMed     Abstract available


  101. PRICE A, Sumner P, Powell G
    Subjective sensory sensitivity and its relationship with anxiety in people with probable migraine.
    Headache. 2021;61:1342-1350.
    PubMed     Abstract available


  102. NABITY PS, Jaramillo CA, Resick PA, McGeary CA, et al
    Persistent posttraumatic headaches and functioning in veterans: Injury type can matter.
    Headache. 2021;61:1334-1341.
    PubMed     Abstract available


  103. STRAUSS LD, Yugrakh MS, Kaplan KE, Minen MT, et al
    Headache infusion centers: A survey on treatments provided, infusion center operations, and barriers to developing new infusion centers.
    Headache. 2021;61:1364-1375.
    PubMed     Abstract available


    September 2021
  104. DODICK DW, Tepper SJ, Ailani J, Pannacciulli N, et al
    Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data.
    Headache. 2021 Sep 30. doi: 10.1111/head.14208.
    PubMed     Abstract available


  105. KLEIN A, Schankin CJ
    Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: A narrative review.
    Headache. 2021 Sep 27. doi: 10.1111/head.14213.
    PubMed     Abstract available


  106. MARMURA MJ, Diener HC, Cowan RP, Tepper SJ, et al
    Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
    Headache. 2021 Sep 22. doi: 10.1111/head.14206.
    PubMed     Abstract available


  107. CHARLES A
    Memantine for migraine-Big promise but little evidence.
    Headache. 2021;61:1151-1152.
    PubMed    


  108. SENG EK
    Stress and migraine: I know it when I see it.
    Headache. 2021;61:1153-1155.
    PubMed    


  109. YALINAY DIKMEN P, Ertas M, Kosak S, Cimentepe C, et al
    Primary headaches among gender dysphoric female-to-male individuals: A cross-sectional survey on gender transition experience.
    Headache. 2021;61:1194-1206.
    PubMed     Abstract available


  110. HOULE TT, Deng H, Tegeler CH, Turner DP, et al
    Continuous updating of individual headache forecasting models using Bayesian methods.
    Headache. 2021;61:1264-1273.
    PubMed     Abstract available


  111. BREEN ID, Mangold AR, VanderPluym JH
    The evolving understanding of risk with calcitonin gene-related peptide monoclonal antibodies based on real-world data: A focus on hypertension and Raynaud phenomenon.
    Headache. 2021;61:1274-1276.
    PubMed    


  112. FREITAG FG
    Everything old is new again.
    Headache. 2021;61:1286.
    PubMed    


    August 2021
  113. KIM SK, Nikolova S, Schwedt TJ
    Structural aberrations of the brain associated with migraine: A narrative review.
    Headache. 2021 Aug 18. doi: 10.1111/head.14189.
    PubMed     Abstract available


  114. SPIERINGS ELH, Ning X, Ramirez Campos V, Cohen JM, et al
    Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b
    Headache. 2021 Aug 10. doi: 10.1111/head.14196.
    PubMed     Abstract available


  115. VIVES-MESTRES M, Casanova A, Hershey AD, Orr SL, et al
    Perceived stress and pain severity in individuals with chronic migraine: A longitudinal cohort study using daily prospective diary data.
    Headache. 2021 Aug 9. doi: 10.1111/head.14199.
    PubMed     Abstract available


  116. ZHANG N, Woldeamanuel YW
    Medication overuse headache in patients with chronic migraine using cannabis: A case-referent study.
    Headache. 2021 Aug 9. doi: 10.1111/head.14195.
    PubMed     Abstract available


  117. TEPPER SJ, Lucas S, Ashina M, Schwedt TJ, et al
    Timing and durability of response to erenumab in patients with chronic migraine.
    Headache. 2021 Aug 7. doi: 10.1111/head.14193.
    PubMed     Abstract available


  118. SMITH TR, Winner P, Aurora SK, Jeleva M, et al
    STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD((R)) ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.
    Headache. 2021 Aug 7. doi: 10.1111/head.14184.
    PubMed     Abstract available


  119. CARONNA E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P, et al
    Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenarios.
    Headache. 2021 Aug 7. doi: 10.1111/head.14197.
    PubMed     Abstract available


  120. COHEN F, Friedman BW
    A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine-associated symptoms: A post hoc analysis.
    Headache. 2021 Aug 7. doi: 10.1111/head.14185.
    PubMed     Abstract available


  121. MISTRY VM, Morizio PL, Pepin MJ, Bryan WE, et al
    Role of memantine in the prophylactic treatment of episodic migraine: A systematic review.
    Headache. 2021 Aug 5. doi: 10.1111/head.14186.
    PubMed     Abstract available


    July 2021
  122. SAKAI F, Suzuki N, Kim BK, Igarashi H, et al
    Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
    Headache. 2021 Jul 29. doi: 10.1111/head.14169.
    PubMed     Abstract available


  123. SAKAI F, Suzuki N, Kim BK, Tatsuoka Y, et al
    Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
    Headache. 2021 Jul 29. doi: 10.1111/head.14178.
    PubMed     Abstract available


  124. BARBANTI P, Aurilia C, Cevoli S, Egeo G, et al
    Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Headache. 2021 Jul 26. doi: 10.1111/head.14194.
    PubMed     Abstract available


  125. ARCA KN, VanderPluym JH, Halker Singh RB
    Narrative review of neuroimaging in migraine with aura.
    Headache. 2021 Jul 26. doi: 10.1111/head.14191.
    PubMed     Abstract available


  126. THOMSEN AV, Sorensen MT, Ashina M, Hougaard A, et al
    Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity.
    Headache. 2021 Jul 12. doi: 10.1111/head.14187.
    PubMed     Abstract available


  127. SAMPAIO ROCHA-FILHO PA, Albanes Oliveira Bernardo A
    The usefulness of osmophobia for the diagnosis of migraine in children and adolescents.
    Headache. 2021 Jul 4. doi: 10.1111/head.14175.
    PubMed    


  128. ISHII R
    Should chronic migraine be defined by eight or more headache days per month?
    Headache. 2021;61:983-984.
    PubMed    


  129. WELLS RE, Estave PM, Burch R, Haas N, et al
    The value of the patient perspective in understanding the full burden of migraine.
    Headache. 2021;61:985-987.
    PubMed    


  130. MINEN MT, Szperka CL, Kaplan K, Ehrlich A, et al
    Telehealth as a new care delivery model: The headache provider experience.
    Headache. 2021;61:1123-1131.
    PubMed     Abstract available


  131. KUMAR G, Payne AM, Maag LM, MacDonald S, et al
    Efficacy of a pediatric headache infusion center: A single-center experience.
    Headache. 2021;61:1086-1091.
    PubMed     Abstract available


  132. CARLSEN LN, Rouw C, Westergaard ML, Nielsen M, et al
    Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial.
    Headache. 2021;61:1112-1122.
    PubMed     Abstract available


    June 2021
  133. AILANI J, Burch RC, Robbins MS
    The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
    Headache. 2021 Jun 23. doi: 10.1111/head.14153.
    PubMed     Abstract available


  134. TAKESHIMA T, Sakai F, Hirata K, Imai N, et al
    Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Headache. 2021 Jun 21. doi: 10.1111/head.14138.
    PubMed     Abstract available


  135. RIZZOLI PB, Grazzi L
    Adaptation of the management of chronic migraine patients with medication overuse to the suspension of treatment protocols during the COVID-19 pandemic: Lessons from a tertiary headache center in Milan-6-month results.
    Headache. 2021 Jun 21. doi: 10.1111/head.14140.
    PubMed    


  136. BHARADWAJ VN, Porreca F, Cowan RP, Kori S, et al
    A new hypothesis linking oxytocin to menstrual migraine.
    Headache. 2021 Jun 14. doi: 10.1111/head.14152.
    PubMed     Abstract available


  137. BARBANTI P, Fofi L, Grazzi L, Vernieri F, et al
    Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) project.
    Headache. 2021 Jun 14. doi: 10.1111/head.14123.
    PubMed     Abstract available


  138. GRAZZI L, Andrasik F, Rizzoli P, Bernstein C, et al
    Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation.
    Headache. 2021 Jun 11. doi: 10.1111/head.14139.
    PubMed     Abstract available


  139. ASHINA M, Cohen JM, Gandhi SK, Du E, et al
    Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
    Headache. 2021 Jun 11. doi: 10.1111/head.14127.
    PubMed     Abstract available


  140. SILVA-NETO RP
    Could osmophobia be a clinical diagnostic marker for migraine?
    Headache. 2021 Jun 9. doi: 10.1111/head.14148.
    PubMed    


  141. KIM BK, Cho S, Kim HY, Chu MK, et al
    Validity and reliability of the self-administered Visual Aura Rating Scale questionnaire for migraine with aura diagnosis: A prospective clinic-based study.
    Headache. 2021 Jun 9. doi: 10.1111/head.14133.
    PubMed     Abstract available


  142. ISHII R, Schwedt TJ, Dumkrieger G, Lalvani N, et al
    Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency.
    Headache. 2021 Jun 3. doi: 10.1111/head.14154.
    PubMed     Abstract available


  143. ESTAVE PM, Beeghly S, Anderson R, Margol C, et al
    Learning the full impact of migraine through patient voices: A qualitative study.
    Headache. 2021 Jun 3. doi: 10.1111/head.14151.
    PubMed     Abstract available


  144. SCHUSTER NM, Gasperi M
    Not just preaching to the CHOIR-A map for improving comprehensive care of patients with chronic migraine and comorbid non-cephalic pain.
    Headache. 2021;61:805-807.
    PubMed    


  145. JOSHI S, Tepper SJ, Lucas S, Rasmussen S, et al
    A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management.
    Headache. 2021;61:838-853.
    PubMed     Abstract available


  146. LIANG Z, Thomas L, Jull G, Minto J, et al
    Neck pain associated with migraine does not necessarily reflect cervical musculoskeletal dysfunction.
    Headache. 2021;61:882-894.
    PubMed     Abstract available


  147. NAHMAN-AVERBUCH H, Hershey AD, Peugh JL, King CD, et al
    The promise of mechanistic approaches to understanding how youth with migraine get better-An Editorial to the 2020 Members' Choice Award Paper.
    Headache. 2021;61:803-804.
    PubMed    


  148. BARAD MJ, Sturgeon JA, Hong J, Aggarwal AK, et al
    Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR study.
    Headache. 2021;61:872-881.
    PubMed     Abstract available


    May 2021
  149. POPOFF E, Johnston K, Croop R, Thiry A, et al
    Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Headache. 2021 May 22. doi: 10.1111/head.14128.
    PubMed     Abstract available


  150. CHIANG CC, Halker Singh R, Lalvani N, Shubin Stein K, et al
    Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey study.
    Headache. 2021 May 21. doi: 10.1111/head.14110.
    PubMed     Abstract available


  151. LIPTON RB, Dodick DW, Ailani J, McGill L, et al
    Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
    Headache. 2021 May 20. doi: 10.1111/head.14120.
    PubMed     Abstract available


  152. SAKAI F, Takeshima T, Homma G, Tanji Y, et al
    Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
    Headache. 2021 May 15. doi: 10.1111/head.14122.
    PubMed     Abstract available


  153. ZIPLOW J
    The importance of studying comorbidities in migraine.
    Headache. 2021;61:697.
    PubMed    


  154. GREENE KA
    The status of intravenous dihydroergotamine for pediatric headache: Status migrainosus and beyond.
    Headache. 2021;61:698-699.
    PubMed    


    April 2021
  155. JAKATE A, Blumenfeld AM, Boinpally R, Butler M, et al
    Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Headache. 2021 Apr 5. doi: 10.1111/head.14095.
    PubMed     Abstract available


  156. YIN JH, Lin YK, Yang CP, Liang CS, et al
    Prevalence and association of lifestyle and medical-, psychiatric-, and pain-related comorbidities in patients with migraine: A cross-sectional study.
    Headache. 2021 Apr 5. doi: 10.1111/head.14106.
    PubMed     Abstract available


  157. AURORA SK, Shrewsbury SB, Ray S, Hindiyeh N, et al
    A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.
    Headache. 2021 Apr 1. doi: 10.1111/head.14099.
    PubMed     Abstract available


  158. BUSE DC, Armand CE, Charleston L 4th, Reed ML, et al
    Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study.
    Headache. 2021 Apr 1. doi: 10.1111/head.14103.
    PubMed     Abstract available


  159. HODGSON SE, Harding AM, Bourke EM, Taylor DM, et al
    A prospective, randomized, double-blind trial of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department.
    Headache. 2021 Apr 1. doi: 10.1111/head.14091.
    PubMed     Abstract available


  160. LIPTON RB, Cohen JM, Galic M, Seminerio MJ, et al
    Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.
    Headache. 2021;61:662-672.
    PubMed     Abstract available


  161. MARMURA MJ
    Comparing treatments in the emergency department: What works for migraine?
    Headache. 2021;61:567-568.
    PubMed    


  162. HINES DM, Shah S, Multani JK, Wade RL, et al
    Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Headache. 2021;61:590-602.
    PubMed     Abstract available


    March 2021
  163. NAEGEL S, Burow P, Holle D, Stoevesandt D, et al
    Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: A case report.
    Headache. 2021 Mar 29. doi: 10.1111/head.14101.
    PubMed    


  164. TRIVEDI M, Dumkrieger G, Chong CD, Dodick DW, et al
    Impact of abuse on migraine-related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research.
    Headache. 2021 Mar 29. doi: 10.1111/head.14100.
    PubMed     Abstract available


  165. SAKAI F, Takeshima T, Tatsuoka Y, Hirata K, et al
    Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Headache. 2021 Mar 25. doi: 10.1111/head.14096.
    PubMed     Abstract available


  166. LIU Y, Xu F, Wheaton AG, Greenlund KJ, et al
    The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015-2016.
    Headache. 2021 Mar 23. doi: 10.1111/head.14087.
    PubMed     Abstract available


  167. VGONTZAS A, Li W, Mostofsky E, Mittleman MA, et al
    Baseline sleep quality, stress, and depressive symptoms, and subsequent headache occurrence in a six-week prospective cohort study of patients with episodic migraine.
    Headache. 2021 Mar 22. doi: 10.1111/head.14105.
    PubMed     Abstract available


  168. WITTEN A, Marotta D, Cohen-Gadol A
    Developmental innervation of cranial dura mater and migraine headache: A narrative literature review.
    Headache. 2021 Mar 22. doi: 10.1111/head.14102.
    PubMed     Abstract available


  169. COWAN RP, Gross NB, Sweeney MD, Sagare AP, et al
    Evidence that blood-CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen.
    Headache. 2021 Mar 16. doi: 10.1111/head.14088.
    PubMed     Abstract available


  170. BLUMENFELD AM, Goadsby PJ, Dodick DW, Hutchinson S, et al
    Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
    Headache. 2021;61:422-429.
    PubMed     Abstract available


    February 2021
  171. ASHINA H, Moskowitz MA
    Shared biological foundations of post-traumatic headache and migraine.
    Headache. 2021 Feb 25. doi: 10.1111/head.14084.
    PubMed    


  172. MCGINLEY JS, Wirth RJ, Pavlovic JM, Donoghue S, et al
    Between and within-woman differences in the association between menstruation and migraine days.
    Headache. 2021 Feb 19. doi: 10.1111/head.14058.
    PubMed     Abstract available


  173. MCGINLEY JS, Houts CR, Nishida TK, Buse DC, et al
    Systematic review of outcomes and endpoints in preventive migraine clinical trials.
    Headache. 2021 Feb 18. doi: 10.1111/head.14069.
    PubMed     Abstract available


  174. SHAO Q, Rascati KL, Lawson KA, Wilson JP, et al
    Impact of emergency department opioid use on future health resource utilization among patients with migraine.
    Headache. 2021 Feb 18. doi: 10.1111/head.14071.
    PubMed     Abstract available


  175. KAWATA AK, Shah N, Poon JL, Shaffer S, et al
    Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
    Headache. 2021 Feb 16. doi: 10.1111/head.14053.
    PubMed     Abstract available


  176. GELFAND AA, Ross AC, Pavitt S, Szperka CL, et al
    Would chronotype change the impact of the relationship between early school schedules and adolescent migraine frequency? A response.
    Headache. 2021 Feb 5. doi: 10.1111/head.14061.
    PubMed    


  177. GELFAND AA, Poland G
    Migraine treatment and COVID-19 vaccines: no cause for concern.
    Headache. 2021 Feb 5. doi: 10.1111/head.14086.
    PubMed     Abstract available


  178. VANDERPLUYM JH
    Once too many: Impact of emergency department opioid use on future health resource utilization among patients with migraine.
    Headache. 2021;61:229-230.
    PubMed    


  179. BURCH R
    Outcomes in clinical trials for migraine: What should we measure and who should decide?
    Headache. 2021;61:227-228.
    PubMed    


  180. HOUTS CR, McGinley JS, Nishida TK, Buse DC, et al
    Systematic review of outcomes and endpoints in acute migraine clinical trials.
    Headache. 2021;61:263-275.
    PubMed     Abstract available


  181. PINTO MJ, Guerrero AL, Costa A
    Botulinum toxin as a novel therapeutic approach for auriculotemporal neuralgia.
    Headache. 2021;61:392-395.
    PubMed     Abstract available


    January 2021
  182. SLAVIN M, Li H, Khatri M, Frankenfeld C, et al
    Dietary magnesium and migraine in adults: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2001-2004.
    Headache. 2021 Jan 27. doi: 10.1111/head.14065.
    PubMed     Abstract available


  183. SPECK RM, Yu R, Ford JH, Ayer DW, et al
    Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.
    Headache. 2021 Jan 22. doi: 10.1111/head.14031.
    PubMed     Abstract available


  184. NEIVA GR, Meira E Cruz M, Salles C
    Would chronotype change the impact of the relationship between early school schedules and adolescent migraine frequency?
    Headache. 2021 Jan 20. doi: 10.1111/head.14060.
    PubMed    


  185. SCHWEDT TJ, Hentz JG, Sahai-Srivastava S, Spare NM, et al
    Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial.
    Headache. 2021 Jan 12. doi: 10.1111/head.14056.
    PubMed     Abstract available


  186. PAVLOVIC JM, Yu JS, Silberstein SD, Reed ML, et al
    Evaluation of the 6-item Identify Chronic Migraine screener in a large medical group.
    Headache. 2021 Jan 9. doi: 10.1111/head.14035.
    PubMed     Abstract available


  187. LIAMPAS I, Mylonas KS, Brotis A, Dervenis P, et al
    Serum lipid abnormalities in migraine: A meta-analysis of observational studies.
    Headache. 2021 Jan 4. doi: 10.1111/head.14039.
    PubMed     Abstract available


  188. O'BRIEN HL, Halker Singh RB
    Breaking down barriers to care: Understanding migraine knowledge gaps among women's healthcare providers.
    Headache. 2021;61:7-8.
    PubMed    


  189. KARVOUNIDES D, Marzouk M, Ross AC, VanderPluym JH, et al
    The intersection of COVID-19, school, and headaches: Problems and solutions.
    Headache. 2021;61:190-201.
    PubMed     Abstract available


  190. BERTELS Z, Witkowski WD, Asif S, Siegersma K, et al
    A non-convulsant delta-opioid receptor agonist, KNT-127, reduces cortical spreading depression and nitroglycerin-induced allodynia.
    Headache. 2021;61:170-178.
    PubMed     Abstract available


    December 2020
  191. OSWALD JC, Schuster NM
    A randomized, double-dummy, emergency department-based study of greater occipital nerve block with bupivacaine versus intravenous metoclopramide for treatment of migraine: A comment.
    Headache. 2020 Dec 31. doi: 10.1111/head.14044.
    PubMed    


  192. SPECTOR AR, Kerkow JF, Collins TA
    Sleep terrors prodromal for migraine headaches responsive to galcanezumab: A case report.
    Headache. 2020 Dec 31. doi: 10.1111/head.14055.
    PubMed    


  193. CONNELLY MA, Boorigie ME
    Feasibility of using "SMARTER" methodology for monitoring precipitating conditions of pediatric migraine episodes.
    Headache. 2020 Dec 31. doi: 10.1111/head.14028.
    PubMed     Abstract available


  194. CHENG V, Billups SJ, Saseen JJ
    Prescribing practices of migraine-specific pharmacotherapy associated with emergency department use for migraine.
    Headache. 2020 Dec 30. doi: 10.1111/head.14029.
    PubMed     Abstract available


  195. VERHAAK AMS, Williamson A, Johnson A, Murphy A, et al
    Migraine diagnosis and treatment: A knowledge and needs assessment of women's healthcare providers.
    Headache. 2020 Dec 30. doi: 10.1111/head.14027.
    PubMed     Abstract available


  196. PRESSMAN AR, Buse DC, Jacobson AS, Vaidya SJ, et al
    The migraine signature study: Methods and baseline results.
    Headache. 2020 Dec 23. doi: 10.1111/head.14033.
    PubMed     Abstract available


  197. BURCH R, Rizzoli P, Loder E
    The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys.
    Headache. 2020 Dec 21. doi: 10.1111/head.14024.
    PubMed     Abstract available


  198. HAGAN KK, Li W, Mostofsky E, Bertisch SM, et al
    Prospective cohort study of routine exercise and headache outcomes among adults with episodic migraine.
    Headache. 2020 Dec 21. doi: 10.1111/head.14037.
    PubMed     Abstract available


  199. HERSHEY AD, Lin T, Gruper Y, Harris D, et al
    Remote electrical neuromodulation for acute treatment of migraine in adolescents.
    Headache. 2020 Dec 21. doi: 10.1111/head.14042.
    PubMed     Abstract available


  200. BARBANTI P, Aurilia C, Egeo G, Fofi L, et al
    Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Headache. 2020 Dec 18. doi: 10.1111/head.14032.
    PubMed     Abstract available


  201. TORABI SJ, Kasle DA, Savoca EL, Gottschalk CH, et al
    Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population.
    Headache. 2020 Dec 18. doi: 10.1111/head.14040.
    PubMed     Abstract available


  202. LIPTON RB, Buse DC, Dodick DW, Schwedt TJ, et al
    Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study.
    Headache. 2020 Dec 16. doi: 10.1111/head.14018.
    PubMed     Abstract available


  203. SMITH M, Nakamoto M, Crocker J, Tiffany Morden F, et al
    Early impact of the COVID-19 pandemic on outpatient migraine care in Hawaii: Results of a quality improvement survey.
    Headache. 2020 Dec 14. doi: 10.1111/head.14030.
    PubMed     Abstract available


  204. DIENER HC, Marmura MJ, Tepper SJ, Cowan R, et al
    Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
    Headache. 2020 Dec 13. doi: 10.1111/head.14036.
    PubMed     Abstract available


    November 2020
  205. GELFAND AA, Pavitt S, Ross AC, Szperka CL, et al
    Later high school start time is associated with lower migraine frequency in adolescents.
    Headache. 2020 Nov 25. doi: 10.1111/head.14016.
    PubMed     Abstract available


  206. NAHMAN-AVERBUCH H, Thomas PL, Schneider VJ 2nd, Chamberlin LA, et al
    Spatial aspects of pain modulation are not disrupted in adolescents with migraine.
    Headache. 2020 Nov 24. doi: 10.1111/head.14017.
    PubMed     Abstract available


  207. TIRITICCO M, Vanotti A, Mantica D, Coppola A, et al
    Migraine With Exclusive Olfactory Aura: Case Report and Literature Review.
    Headache. 2020 Nov 18. doi: 10.1111/head.14014.
    PubMed     Abstract available


  208. MINEN MT, Adhikari S, Padikkala J, Tasneem S, et al
    Smartphone-Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial.
    Headache. 2020 Nov 16. doi: 10.1111/head.14010.
    PubMed     Abstract available


  209. LIPTON RB, Cohen JM, Bibeau K, Galic M, et al
    Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
    Headache. 2020 Nov 11. doi: 10.1111/head.13997.
    PubMed     Abstract available


  210. POLK AN, Protti TA, Smitherman TA
    Allodynia and Disability in Migraine: The Mediating Role of Stress.
    Headache. 2020 Nov 9. doi: 10.1111/head.14012.
    PubMed     Abstract available


  211. DODICK DW, Gottschalk C, Cady R, Hirman J, et al
    Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.
    Headache. 2020 Nov 9. doi: 10.1111/head.14007.
    PubMed     Abstract available


  212. PILATI L, Battaglia G, Di Stefano V, Di Marco S, et al
    Migraine and Sport in a Physically Active Population of Students: Results of a Cross-Sectional Study.
    Headache. 2020 Nov 7. doi: 10.1111/head.14015.
    PubMed     Abstract available


  213. GILL K, Chia VM, Hernandez RK, Navetta M, et al
    Rates of Vascular Events in Patients With Migraine: A MarketScan((R)) Database Retrospective Cohort Study.
    Headache. 2020 Nov 3. doi: 10.1111/head.14001.
    PubMed     Abstract available


  214. BUSE DC, McGinley JS, Lipton RB
    Predicting the Future of Migraine Attack Prediction.
    Headache. 2020;60:2125-2128.
    PubMed    


  215. VGONTZAS A, Li W, Mostofsky E, Mittleman MA, et al
    The Sleep - Migraine Enigma: A Comment.
    Headache. 2020;60:2610.
    PubMed    


  216. FORD JH, Kurth T, Starling AJ, Ayer DW, et al
    Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
    Headache. 2020;60:2304-2319.
    PubMed     Abstract available


    October 2020
  217. ANDERSON CC, Ray CA, Butler MR, Darken RS, et al
    Effects of Procedural Discomfort and Expectation of Benefit on Therapy Continuation in Chronic Migraine Patients Treated With OnabotulinumtoxinA.
    Headache. 2020 Oct 31. doi: 10.1111/head.14008.
    PubMed     Abstract available


  218. BOLAY H, Ozge A, Uluduz D, Baykan B, et al
    Are Migraine Patients at Increased Risk for Symptomatic Coronavirus Disease 2019 Due to Shared Comorbidities?
    Headache. 2020 Oct 30. doi: 10.1111/head.13998.
    PubMed     Abstract available


  219. KRYMCHANTOWSKI A, Jevoux C, Silva-Neto RP, Krymchantowski AG, et al
    Migraine Treatment in Emergency Departments of Brazil: A Retrospective Study of 2 Regions.
    Headache. 2020 Oct 27. doi: 10.1111/head.13999.
    PubMed     Abstract available


  220. BLUMENFELD AM, Silberstein SD
    Response to "Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice".
    Headache. 2020 Oct 27. doi: 10.1111/head.13996.
    PubMed    


  221. SMITHERMAN TA, Tietjen GE, Schuh K, Skljarevski V, et al
    Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
    Headache. 2020 Oct 16. doi: 10.1111/head.13970.
    PubMed     Abstract available


  222. BUSE DC, Reed ML, Fanning KM, Bostic RC, et al
    Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Headache. 2020 Oct 14. doi: 10.1111/head.13966.
    PubMed     Abstract available


  223. TU S, Liew D, Ademi Z, Owen AJ, et al
    The Health and Productivity Burden of Migraines in Australia.
    Headache. 2020 Oct 7. doi: 10.1111/head.13969.
    PubMed     Abstract available


  224. HOLSTEEN KK, Hittle M, Barad M, Nelson LM, et al
    Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger Exposures.
    Headache. 2020 Oct 6. doi: 10.1111/head.13960.
    PubMed     Abstract available


  225. BEUTHIN J, Veronesi M, Grosberg B, Evans RW, et al
    Gluten-Free Diet and Migraine.
    Headache. 2020 Oct 6. doi: 10.1111/head.13993.
    PubMed     Abstract available


  226. GHANSHANI S, Chen C, Lin B, Duan L, et al
    Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans.
    Headache. 2020 Oct 5. doi: 10.1111/head.13959.
    PubMed     Abstract available


  227. TOMKINS E, Craven A, Ruttledge M
    Migraine and Headache Care in the Republic of Ireland: History and a Vision for the Future Influenced by the COVID-19 Pandemic.
    Headache. 2020 Oct 3. doi: 10.1111/head.13985.
    PubMed     Abstract available


    September 2020
  228. SWART ECS, Good CB, Henderson R, Manolis C, et al
    Identifying Outcome Measures for Migraine Value-Based Contracting Using the Delphi Method.
    Headache. 2020 Sep 30. doi: 10.1111/head.13978.
    PubMed     Abstract available


  229. CHENG S, Jenkins B, Limberg N, Hutton E, et al
    Erenumab in Chronic Migraine: An Australian Experience.
    Headache. 2020 Sep 29. doi: 10.1111/head.13968.
    PubMed     Abstract available


  230. HAMILTON KT, Halker Singh RB, Ailani J, Butterfield RJ, et al
    Migraine Treatment in Pregnancy: An American Headache Society Survey.
    Headache. 2020 Sep 29. doi: 10.1111/head.13974.
    PubMed    


  231. FRIEDMAN BW, Irizarry E, Williams A, Solorzano C, et al
    A Randomized, Double-Dummy, Emergency Department-Based Study of Greater Occipital Nerve Block With Bupivacaine vs Intravenous Metoclopramide for Treatment of Migraine.
    Headache. 2020 Sep 27. doi: 10.1111/head.13961.
    PubMed     Abstract available


  232. QUINTAS M, Neto JL, Sequeiros J, Sousa A, et al
    Going Deep into Synaptic Vesicle Machinery Genes and Migraine Susceptibility - A Case-Control Association Study.
    Headache. 2020 Sep 26. doi: 10.1111/head.13957.
    PubMed     Abstract available


  233. TOPTAN T, Aktan C, Basari A, Bolay H, et al
    Case Series of Headache Characteristics in COVID-19: Headache Can Be an Isolated Symptom.
    Headache. 2020;60:1788-1792.
    PubMed     Abstract available


  234. SAMPAIO ROCHA-FILHO PA, Voss L
    Persistent Headache and Persistent Anosmia Associated With COVID-19.
    Headache. 2020;60:1797-1799.
    PubMed    


  235. PORTA-ETESSAM J, Matias-Guiu JA, Gonzalez-Garcia N, Gomez Iglesias P, et al
    Spectrum of Headaches Associated With SARS-CoV-2 Infection: Study of Healthcare Professionals.
    Headache. 2020;60:1697-1704.
    PubMed     Abstract available


  236. BOBKER SM, Robbins MS
    COVID-19 and Headache: A Primer for Trainees.
    Headache. 2020;60:1806-1811.
    PubMed     Abstract available


  237. LIPTON RB, Seng EK, Chu MK, Reed ML, et al
    The Effect of Psychiatric Comorbidities on Headache-Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
    Headache. 2020;60:1683-1696.
    PubMed     Abstract available


    July 2020
  238. MINEN MT, Jaran J, Boyers T, Corner S, et al
    Understanding What People With Migraine Consider to be Important Features of Migraine Tracking: An Analysis of the Utilization of Smartphone-Based Migraine Tracking With a Free-Text Feature.
    Headache. 2020;60:1402-1414.
    PubMed     Abstract available


  239. SUZUKI K, Fujita H, Hirata K
    Parkinson's Disease and Headache: Is there a Relevant Relationship?
    Headache. 2020;60:1440-1441.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: